Clinical trials
Allogeneic Disease clinical trials
Below are recruiting allogeneic disease clinical trials, each written for real people, not researchers. We’re tracking 92 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05470491RecruitingPhase 1/Phase 2
Haploidentical bone marrow transplant with GVHD prevention drugs
This trial tests a reduced-intensity bone marrow transplant from a related donor (haploidentical), using medicines to help prevent a serious complication called GVHD. It is for people with certain blood cancers and aims to improve outcomes by balancing transplant benefit with lower treatment intensity.
Bethesda, MarylandAges 12–120 - NCT07374679Recruiting
Long-term safety and effectiveness of stem cells for rotator cuff disease
This study follows up with people who already received an experimental stem cell treatment for rotator cuff disease in a previous trial. It aims to check if the treatment remains safe and effective over time.
Seoul, KoreaAges 19 years+ - NCT06733610RecruitingPhase 1
CAR T-cell therapy for AIHA after 3 failed treatments
This trial tests a new type of immunotherapy called CAR T-cell therapy that targets two markers on your immune cells (CD19 and BCMA). It is for people with autoimmune hemolytic anemia (AIHA) who have already tried at least 3 standard treatments without success.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06615050RecruitingPhase 3
Comparing two drug combinations for stem cell transplant
This trial tests two different combinations of medicines to prevent graft-versus-host disease (when donor cells attack your body) after a stem cell transplant. The goal is to see which approach works better for people with certain blood cancers or lymphomas.
Palo Alto, CaliforniaAges 18 years+ - NCT06636032RecruitingPhase 1/Phase 2
Stem cells for Crohn's fistula treatment
This trial tests whether injecting donated stem cells into complex anal fistulas can help heal them in people with Crohn's disease. You may qualify if you have a fistula that hasn't improved with standard treatments.
ToulouseAges 18 years+ - NCT07493161Recruiting
Chemo with targeted therapy for new Ph+ ALL
This trial tests a combination of chemotherapy and targeted immunotherapy for people with a specific type of leukemia (Ph+ ALL) that has not been treated before. The goal is to see if this approach can help control the disease better.
Tianjin, Tianjin MunicipalityAges 14 years+ - NCT05003947RecruitingPhase 1
Stem cell infusion for Crohn’s or ulcerative colitis safety
This Phase 1 trial tests whether an IV infusion of donated (allogeneic) stem cells is safe in people with Crohn’s disease or ulcerative colitis. It focuses mainly on safety and tolerability, and it may offer a new treatment approach if you qualify.
St John'sAges Any age - NCT05018845RecruitingPhase 1
Testing a donated stem cell treatment for chronic kidney disease
This early study (Phase 1) tests whether an intravenously given, donated stem cell product is safe for people with chronic kidney disease. It mainly looks at side effects and whether the treatment can be given without harming you.
St John'sAges Any age - NCT07304232RecruitingPhase 2
Chidamide after stem cell transplant for AML
This trial tests a drug called chidamide (Cidabenamide) as maintenance therapy after a stem cell transplant for people with intermediate or high-risk AML. The goal is to see if it helps prevent the leukemia from coming back.
Shijiazhuang, HebeiAges 18–75 - NCT07029958RecruitingPhase 4
Transplant protocol for EBV-related T/NK lymphoproliferative disease
This trial tests a stronger transplant conditioning regimen to treat a rare immune disorder caused by the Epstein-Barr virus. It aims to improve outcomes and reduce a complication called graft-versus-host disease, where donor cells attack the patient's body.
BeijingAges birth–18 years - NCT06017869RecruitingPhase 2
Mitochondria therapy for Pearson Syndrome in children
This trial tests a one-time infusion of your own blood cells mixed with donated mitochondria to see if it can help children with Pearson Syndrome grow better and improve their health. It is a new approach that aims to provide the energy your cells need.
Ramat Gan, IsraelAges 1–18 - NCT01166009Recruiting
CIBMTR research database for transplant and bone marrow injury patients
This study collects health and treatment information in a large research database. It may help researchers better understand outcomes after blood stem cell transplants or bone marrow injury from treatment like radiation.
Minneapolis, MinnesotaAges Any age - NCT04339777RecruitingPhase 2
Bone marrow transplant for inherited immune system disorders
This trial studies how well a donor bone marrow (stem cell) transplant works for people with inherited immune system problems (called immune deficiencies). It’s for patients who haven’t improved with usual treatment or don’t have another good option.
Bethesda, MarylandAges 4–69 - NCT07072247RecruitingPhase 1
RN1201 injection for hard-to-treat antibody-mediated blood disorders
This trial tests a new injection called RN1201 for people with antibody-mediated diseases, specifically two types of blood disorders: platelet transfusion refractoriness (PTR) and immune thrombocytopenia (ITP) that haven't responded to standard treatments. The goal is to see if RN1201 can help control these conditions.
Suzhou, JiangsuAges 16–65 - NCT02579967RecruitingPhase 2
Stem cell transplant for primary immune system disorders
This study tests whether an allogeneic stem cell (bone marrow) transplant can correct an inherited immune problem in people with severe primary immunodeficiencies. It may help reduce life-threatening infections and improve quality of life, depending on your overall health and donor match.
Bethesda, MarylandAges 4–75 - NCT07493538RecruitingPhase 2
Blood stem cell transplant with lower-intensity chemo for blood cancers
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
Minneapolis, MinnesotaAges 2–75 - NCT03779854RecruitingPhase 2
Preventing graft-versus-host disease in kids after stem cell transplant
This trial tests whether removing certain immune cells (T cells) from the donor transplant can lower the risk of chronic graft-versus-host disease (long-term immune attack after transplant) in children and young adults with blood cancers. If you qualify, it may help improve transplant outcomes while tracking safety and side effects.
Los Angeles, CaliforniaAges 6 months–26 years - NCT06918834RecruitingPhase 2
Immediate vs bridging transplant for high-risk MDS
This trial compares getting a stem cell transplant right away versus getting other treatments first before transplant for people with high-risk myelodysplastic syndrome (MDS), a bone marrow disorder. It aims to see which approach leads to better outcomes.
Beijin, Beijing MunicipalityAges 18 years+ - NCT05436418RecruitingPhase 1/Phase 2
Lower-dose transplant medicines to prevent graft-versus-host disease
This early-phase study tests a lower dose of cyclophosphamide given after a stem cell transplant to prevent graft-versus-host disease (GVHD). It also uses sirolimus and mycophenolate to improve how well the donor immune system accepts the transplant, aiming to reduce side effects while keeping protection against GVHD.
Duarte, CaliforniaAges 12–120 - NCT03970096RecruitingPhase 2
Reduce graft-versus-host disease after stem cell transplant
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
Tampa, FloridaAges 1–60
Hear when a new Allogeneic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for allogeneic disease?
- Yes. Clin2 currently lists 92 recruiting allogeneic disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a allogeneic disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a allogeneic disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.